For Doctors in a Hurry
- Researchers investigated the rates and clinical predictors of progression from pure autonomic failure to Parkinson disease, dementia with Lewy bodies, and multiple system atrophy.
- This meta-analysis synthesized data from nine longitudinal studies involving 900 patients with pure autonomic failure followed for an average of 6.4 years.
- The pooled incidence rate for phenoconversion was 5.09 per 100 person-years, with 30 percent of patients developing a central alpha-synucleinopathy.
- The researchers concluded that pure autonomic failure often represents a prodromal stage of neurodegenerative disease, with conversion rates similar to sleep behavior disorders.
- Monitoring for hyposmia, sleep behavior disorders, and subtle motor signs may help clinicians identify patients at the highest risk for neurological progression.
Predicting the Trajectory of Pure Autonomic Failure
Pure autonomic failure is a rare neurodegenerative disorder characterized by isolated sympathetic and parasympathetic dysfunction, most commonly manifesting as neurogenic orthostatic hypotension (a significant drop in blood pressure upon standing) [1]. While the pathology is primarily peripheral, involving alpha-synuclein deposition in autonomic ganglia, longitudinal data indicate that a substantial portion of patients will eventually develop central nervous system involvement [2, 3, 4]. Patients often present with non-motor symptoms such as supine hypertension (elevated blood pressure while lying down) and rapid eye movement sleep behavior disorder (a condition where patients physically act out dreams) [5, 6, 7]. Differentiating between those who will remain stable and those destined to develop Parkinson disease, dementia with Lewy bodies, or multiple system atrophy remains a significant diagnostic challenge, as the annual risk of phenoconversion (the transition from a prodromal state to a manifest neurological disease) is difficult to predict [2, 3, 8]. A recent systematic review and meta-analysis provides a framework for estimating these conversion risks and identifying clinical markers that signal impending neurological decline [2].
Quantifying the Risk of Neurological Progression
To establish a definitive timeline for disease progression, researchers analyzed longitudinal data from 9 studies comprising 900 individuals diagnosed with pure autonomic failure. The cohort reflected a predominantly older, male demographic, with a mean age at onset of 63.1 (4.3) years and a composition that was 63.8% male. These baseline characteristics mirror the typical patient population presenting to neurology and cardiology clinics with isolated autonomic dysfunction. Over a mean duration of follow-up of 6.4 (2.0) years, a substantial proportion of the study population progressed to manifest central nervous system involvement. Specifically, 270 of 900 individuals (30%) experienced phenoconversion to a central alpha-synucleinopathy (a class of neurodegenerative diseases characterized by the abnormal accumulation of alpha-synuclein protein in the brain, encompassing Parkinson disease, dementia with Lewy bodies, and multiple system atrophy). The analysis determined a pooled incidence rate of 5.09 per 100 person-years (95% CI, 3.79-6.85) for any central alpha-synucleinopathy. For the practicing physician, this figure translates to an approximate 5% annual risk of neurological progression, a rate that necessitates consistent, long-term clinical surveillance. Furthermore, the statistical variability between the included studies was partly explained by the duration of follow-up. This indicates that the likelihood of observing phenoconversion increases as the period of clinical observation extends, reinforcing the need for serial neurological examinations. By quantifying this risk, the findings provide a concrete prognostic framework for counseling patients, demonstrating that nearly one-third of individuals with pure autonomic failure will develop central neurological deficits within six to seven years of their initial presentation.
Differentiating Between Synucleinopathy Trajectories
The progression from pure autonomic failure to a central nervous system disorder does not follow a single clinical path. Among the study population, phenoconversion occurred in 12% of patients to multiple system atrophy, a rapidly progressive condition characterized by severe autonomic failure combined with parkinsonism or cerebellar ataxia. This was followed closely by phenoconversion in 11% of patients to dementia with Lewy bodies, while 7% of patients progressed to Parkinson disease. These figures underscore that patients initially presenting with isolated autonomic failure most frequently develop multiple system atrophy or dementia with Lewy bodies, rather than idiopathic Parkinson disease. The temporal patterns of these conversions provide critical prognostic guidance. The researchers found that multiple system atrophy phenoconversion rates were highest in the first years of follow-up, yielding a pooled incidence rate of 1.96 per 100 person-years (95% CI, 1.29-2.99). This front-loaded risk profile suggests that if a patient is destined to develop this aggressive phenotype, they will likely do so early in their clinical course. Consequently, physicians should maintain high vigilance for red flags, such as inspiratory stridor or rapid gait deterioration, during the first few years following a pure autonomic failure diagnosis. In contrast, Lewy body disorders showed more constant phenoconversion rates over time, indicating a persistent risk that does not diminish as the years pass. The pooled incidence rate for dementia with Lewy bodies was 1.56 per 100 person-years (95% CI, 0.94-2.61), while the pooled incidence rate for Parkinson disease was 1.35 per 100 person-years (95% CI, 0.75-2.41). For patients who do not convert to multiple system atrophy early on, long-term clinical management must focus on the steady, ongoing possibility of developing motor or cognitive symptoms associated with Lewy body pathology.
Clinical Red Flags for Early Intervention
Identifying which patients with pure autonomic failure will progress to a specific central nervous system disorder requires careful attention to non-autonomic markers. The researchers found that hyposmia (a reduced ability to smell) had diagnostic value to distinguish between phenoconversion to Parkinson disease or dementia with Lewy bodies versus multiple system atrophy. The presence of an olfactory deficit was strongly associated with the Lewy body spectrum of diseases, carrying a pooled risk ratio of 1.88 (95% CI, 1.26-2.97). This suggests that simple bedside smell testing can serve as a highly practical tool for clinicians to refine a patient's expected disease trajectory. Beyond olfactory function, certain neurological and sleep-related symptoms act as universal indicators of impending central nervous system involvement. The study identified that rapid eye movement sleep behavior disorder was a consistent predictor of phenoconversion to any central alpha-synucleinopathy. Similarly, the presence of subtle motor signs were consistent predictors of phenoconversion to any central alpha-synucleinopathy, indicating that even minor changes in gait, posture, or coordination should be viewed as evidence of spreading pathology. These findings emphasize the necessity of routine screening for sleep disturbances and detailed motor examinations during longitudinal care. Ultimately, the researchers concluded that phenoconversion incidence rates in pure autonomic failure are similar to those observed in rapid eye movement sleep behavior disorder, a condition already widely recognized as a high-risk prodromal state. By monitoring a combination of clinical markers, including sleep disturbances, subtle motor signs, and hyposmia, physicians can better identify candidates for specialized monitoring. This approach provides a vital window for early diagnosis before the onset of debilitating motor or cognitive symptoms, allowing for proactive management of these complex neurodegenerative conditions.
References
1. Traon AP, Foubert-Samier A, Fabbri M. An overview on pure autonomic failure.. Revue neurologique. 2024. doi:10.1016/j.neurol.2023.11.003
2. Virameteekul S, Bonini I, Campese N, et al. Phenoconversion in Pure Autonomic Failure: A Systematic Review and Meta-Analysis.. JAMA neurology. 2026. doi:10.1001/jamaneurol.2026.0989
3. Vernetti PM, Norcliffe‐Kaufmann L, Palma J, et al. Phenoconversion in pure autonomic failure: a multicentre prospective longitudinal cohort study. Brain. 2024. doi:10.1093/brain/awae033
4. Chiaro G, Vichayanrat E, Koay S, et al. Pure autonomic failure: a natural history study of the Queen Square cohort. Brain. 2025. doi:10.1093/brain/awaf191
5. Lopes PRM, Filho FLW, Filho FDSMM, Falcão CER, Arca VM, Parmera JB. Prevalence of Supine Hypertension in Alpha-Synucleinopathies: A Systematic Review and Meta-Analysis.. Movement disorders clinical practice. 2025. doi:10.1002/mdc3.70142
6. Postuma RB. Neuroprotective Trials in REM Sleep Behavior Disorder. Neurology. 2022. doi:10.1212/wnl.0000000000200235
7. Koay S, Vichayanrat E, Bremner F, et al. Multimodal Autonomic Biomarkers Predict Phenoconversion in Pure Autonomic Failure. Annals of Clinical and Translational Neurology. 2025. doi:10.1002/acn3.70140
8. Stanković I, Kuijpers M, Kaufmann H. An update on multiple system atrophy. Current Opinion in Neurology. 2024. doi:10.1097/wco.0000000000001285
